spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Hip Fracture 

 HSMN NewsFeed - 1 Feb 2021
X-Bolt Features in Largest Ever Hip Fracture Fixation Trial Publication
Devices Orthopaedic
 HSMN NewsFeed - 19 Oct 2020
Solarea Bio Announces Series A Financing Led by S2G Ventures and Bold Capital Partners
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Oct 2019
EVENITY(R) (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Sep 2019
Largest Ever Hip Fracture Fixation Trial in Over 1,000 Patients Demonstrates Unprecedently Low Cut-Out Rates for X-BOLT(R) Device
Devices Orthopaedic
 HSMN NewsFeed - 20 Aug 2019
Richter Launched Terrosa(R), its Biosimilar Teriparatide Across Europe
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 28 Jun 2019
Amgen and UCB Provide Regulatory Update on Status of EVENITY(TM) (romosozumab) in the EU
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 5 Jun 2019
Smith & Nephew Launches the CONQUEST FN(TM) Femoral Neck Fracture System, a Fresh Approach to Hip Preservation Versus Current Treatment Options
Devices Orthopaedic Product Launch
 HSMN NewsFeed - 8 Jan 2019
EVENITY(TM) (romosozumab) Receives Approval In Japan For The Treatment Of Osteoporosis In Patients At High Risk Of Fracture
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Jul 2018
Amgen And UCB Resubmit Biologics License Application (BLA) For EVENITY(TM) (romosozumab) To The US FDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Jun 2018
European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Apr 2018
Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Oct 2017
New System Designed to Enhance Implant Fixation for Hip Fracture Patients with Poor Bone Quality Launches in the U.S.
Devices Orthopaedic Product Launch
 HSMN NewsFeed - 17 Jul 2017
Amgen And UCB Provide Update On Regulatory Status Of EVENITY(TM) (romosozumab) In The US
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Jul 2017
Viking Therapeutics Completes Enrollment in Phase 2 Study of VK5211 in Patients Recovering from Hip Fracture
Biopharmaceuticals Orthopaedic
 HSMN NewsFeed - 6 Jul 2017
Viking Therapeutics Appoints Charles A. Rowland Jr. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2017
Amgen And UCB Announce Top-Line Phase 3 Data From Active-Comparator Study Of EVENITY(TM) (Romosozumab) In Postmenopausal Women With Osteoporosis
Biopharmaceuticals
 HSMN NewsFeed - 20 Apr 2017
FDA Clears Halyard Health's COOLIEF for the Management of Osteoarthritis Knee Pain
Devices Orthopaedic FDA
 HSMN NewsFeed - 6 Jan 2017
Viking Therapeutics Announces Senior Level Appointments to Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Sep 2014
Mylan to Acquire U.S. Rights to Arixtra(R) (fondaparinux sodium) Injection from Aspen
Biopharmaceuticals Generics
 HSMN NewsFeed - 13 Dec 2011
Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
Biopharmaceuticals
 HSMN NewsFeed - 30 Nov 2011
Abbott Receives FDA Clearance for New Test to Detect Vitamin D Levels
Diagnostics FDA
 HSMN NewsFeed - 22 Apr 2011
Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA(R) (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery
Biopharmaceuticals Surgery Regulatory
 HSMN NewsFeed - 4 Oct 2010
Covidien Demonstrates Breakthroughs in Minimally Invasive Surgery and Soft Tissue Repair at 2010 American College of Surgeons Clinical Congress (ACS)
Devices Surgery
 HSMN NewsFeed - 1 Jun 2010
FDA Approves Amgen's Prolia(TM) (Denosumab) for Treatment of Postmenopausal Women With Osteoporosis at High Risk for Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 May 2010
Prolia(R) (Denosumab) Granted Marketing Authorization in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Nov 2009
Smith & Nephew Orthopaedics Selected to Develop New Technology for Treating Battlefield Injuries
Devices Orthopaedic
 HSMN NewsFeed - 1 Jun 2009
FDA Approves Reclast(R) to Prevent Osteoporosis in Postmenopausal Women With Convenient Less Frequent Dosing
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Apr 2009
KCI and Carroll Hospital Group Inc. Partner to Help Prevent Pressure Ulcers and Reduce Patient Falls
Devices Wound Care
 HSMN NewsFeed - 11 Feb 2009
JFK Memorial Hospital Announces Availability of Personalized Partial Knee Resurfacing System for Patients
Devices Orthopaedic
 HSMN NewsFeed - 8 Dec 2008
First Head-To-Head Study Shows That Protelos(R) (Strontium Ranelate) Builds Better Bone Than Bisphosphonate
Biopharmaceuticals
 HSMN NewsFeed - 25 Sep 2008
Merck & Co., Inc. and Japan Tobacco Inc. Sign Licensing Agreement for Novel Osteoanabolic Drug Candidate to Treat Osteoporosis
Biopharmaceuticals Licensing
 HSMN NewsFeed - 25 Jul 2008
Amgen Announces Positive Top-Line Results for Denosumab Pivotal Postmenopausal Osteoporosis Trial
Biopharmaceuticals
 HSMN NewsFeed - 5 Jun 2008
FDA Broadens US Indication for Once-Yearly Reclast(R) as Only Osteoporosis Treatment Approved for Prevention of Fractures After a Hip Fracture
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jan 2008
Clexane(R)/Lovenox(R) Approved in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Sep 2007
Increased Bone Mineral Density Seen in Phase IIB Study with Odanacatib, Formerly MK-0822, An Investigational Cathepsin K Inhibitor
Biopharmaceuticals
 HSMN NewsFeed - 17 Sep 2007
First Osteoporosis Study in Hip Fracture Patients Finds Once-Yearly Reclast(R) Prevents Additional Fractures and Improves Survival
Biopharmaceuticals
 HSMN NewsFeed - 17 Aug 2007
Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2007
Once-yearly Reclast(R) Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis
Biopharmaceuticals Orthopaedic
 HSMN NewsFeed - 17 Apr 2007
Reclast(R) Receives US Approval as a Highly Effective Treatment for Patients with Paget's Disease of the Bone
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Feb 2007
Initiation of Phase III Program Using Emisphere's eligen(R) Technology for Oral Salmon Calcitonin
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 30 Jan 2007
Agreement between Ipsen and MSD for the Co-Marketing in France of Adrovance(TM) for the Treatment of Postmenopausal Osteoporosis
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Oct 2006
FDA Grants Priority Review for ARIXTRA(R) (fondaparinux sodium) in the Treatment of Acute Coronary Syndromes
Biopharmaceuticals Cardiology FDA
 HSMN NewsFeed - 16 Sep 2006
Once-Yearly Reclast(R)* Demonstrates Highly Significant Fracture Risk Reductions in the Treatment of Postmenopausal Osteoporosis, New Study Shows
Biopharmaceuticals
 HSMN NewsFeed - 12 Jul 2006
Smith & Nephew Launches Innovative TRIGEN(TM) INTERTAN(TM) Nail for Femoral Fractures
Devices Orthopaedic
 HSMN NewsFeed - 5 Jul 2006
Geron Presents New Data That Document Progress in Development of Therapeutic Products from Human Embryonic Stem Cells
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 20 Apr 2006
Biocoral, Inc. Presentation of Prospective Report of its Randomized Clinical Multi-Trial for Treatment of Hip Fracture Associated With Natural Bone Demineralization
Devices Orthopaedic
 HSMN NewsFeed - 11 Apr 2006
New Data From the Women's Health Initiative Study Show No Increased Risk of Breast Cancer with Conjugated Estrogens Alone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Apr 2006
ARIXTRA(R) Significantly Reduced Major Bleeding Compared to LOVENOX(R) in a Study of Patients With Acute Coronary Syndromes
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Mar 2006
Ankle Ailments Get a 'Leg up' with New Treatments and Techniques
Devices Surgery Orthopaedic
 HSMN NewsFeed - 14 Mar 2006
ARIXTRA(R) (Fondaparinux Sodium) Reduced Risk of Death or Recurrent Heart Attack in Patients With Acute Coronary Syndromes (ST Elevation Myocardial Infarction)
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 13 Feb 2006
New Data from Women's Health Initiative Study Show No Increased Risk of Coronary Heart Disease with Conjugated Estrogens Alone In Any Age Group Studied
Biopharmaceuticals
 HSMN NewsFeed - 13 Feb 2006
Pivotal Study Published in British Medical Journal Reports: ARIXTRA(R) Was Effective and Well Tolerated in Acutely Ill Medical Patients - Treatment Reduced Risk of Venous ThromboEmbolism (VTE)
Biopharmaceuticals
 HSMN NewsFeed - 3 Feb 2006
ARIXTRA(R) Administered the Morning After Orthopedic Surgery Prevented Venous Thromboembolism With Low Risk of Bleeding
Biopharmaceuticals Orthopaedic
Return to NewsFeed  

 Additional items found! 35

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 35 additional stories matching:
Hip Fracture
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.